CIA: This is a declassified Drug Enforcement Administration China Country Brief

This is a declassified Drug Enforcement Administration China Country Brief, dated February five, two thousand four. The brief appears in the public record as a non‑classified intelligence briefing on the People's Republic of China, and it is notable for its detailed assessment of drug‑related activity across the nation. The document was released through The Black Vault, uploaded on the archive.org platform. It is part of a Freedom of Information Act release, though the specific FOIA case number is not cited in the accompanying entry. The declassification authority is the United States government, and the file was made publicly accessible on the date of upload. The brief begins with a summary of China’s status in international drug trafficking. It notes that several factors influence China’s role, including history, location, size, population, and current economic conditions. China, with one‑fifth of the world’s population and a large, expanding economy, has a long history of opium use dating back before the Opium Wars of the mid‑nineteenth century. Its extensive landmass, proximity to the Golden Triangle, and numerous modern coastal ports make it an attractive transit center for drug traffickers. The brief observes that China’s role changed significantly after the 1980s, when the country opened its borders to trade and tourism after decades of relative isolation, leading to increased flow of illicit drugs and precursor chemicals. Significant effects of drug trafficking in China are listed as follows: China serves as a transit area for Southeast Asian heroin bound for international markets; it is a key source of crystal methamphetamine used by many Southeast Asian and Pacific Rim nations; it is developing a notable production, trafficking, and consumption problem with 3,4‑methylenedioxymethamphetamine, commonly known as MDMA; and it is a major source of precursor chemicals necessary for the production of cocaine, heroin, crystal methamphetamine, and MDMA. Consequently, China is compelled to develop a complex counter‑drug strategy that includes prevention, education, eradication, interdiction, and rehabilitation. The brief then details cultivation and processing of specific substances. Cannabis grows naturally throughout southwestern China and is licitly cultivated in some areas for commercial rope manufacturing. Illicit cultivation appears primarily in Xinjiang and Yunnan provinces, mainly for domestic use, with approximately 1.3 metric tons of marijuana seized in two thousand two. Ephedra is cultivated under strict government control; the active alkaloids pseudoephedrine and ephedrine are extracted for pharmaceutical purposes and sold domestically and for export. China and India are the major producers of these chemicals. Illicit cultivation of the opium poppy is described as negligible; poppy cultivation occurs in Yunnan, Ningxia, Inner Mongolia, and remote northwest frontier regions, with the product consumed locally by ethnic minority groups. No heroin laboratories have been seized in recent years. Licit opium production, according to United Nations International Narcotics Control Board data, amounts to roughly fourteen metric tons per year for domestic pharmaceutical use, with none exported. Synthetic drug production is addressed next. Manufacture of crystal methamphetamine, known locally as ice, shabu, or bingdu, is facilitated by the unrestricted availability of precursor chemicals such as pseudoephedrine and ephedrine. Methamphetamine laboratories are located in provinces along the eastern and southeastern coasts, with traffickers often linked to organized crime groups based in Hong Kong, Taiwan, and Japan. The brief reports a significant increase in domestic production of MDMA, or ecstasy, especially in Beijing, Shanghai, Nanjing, Guangzhou, and Shenzhen. Most MDMA production is for domestic consumption, though tablets are also imported from the Netherlands. Open‑source reporting indicates that MDMA tablets can be produced for as little as six cents and sold for up to thirty‑six dollars in Shanghai. Regarding trafficking groups, the brief notes that many individuals involved in the international trafficking of Southeast Asian heroin are ethnic Kokang, Yunnanese, Fujianese, Cantonese, or other Chinese minority groups residing outside of China, operating in Burma, Cambodia, Canada, Hong Kong, Taiwan, Thailand, and the United States. Data on drug‑related arrests from nineteen ninety‑one through two thousand three show a trend of traffickers dividing large shipments into smaller